• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.52% Nasdaq Down0.25%

    More On HNCMF

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    Hutchison China MediTech Ltd. (HNCMF)

    -Other OTC
    27.05 0.00(0.00%) Jul 21
    Add to Portfolio
    ProfileGet Profile for:
    Hutchison China MediTech Ltd.
    Hutchison House
    22nd Floor
    Hong Kong,
    Hong Kong - Map
    Phone: 852 2128 1188
    Fax: 852 2128 1778
    Website: http://www.chi-med.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:N/A

    Business Summary 

    Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People’s Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn’s disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Hutchison China MediTech Ltd.

    Key Executives 
     PayExercised
    Mr. Simon To BSc, ACGI, MBA, 63
    Exec. Chairman, Chairman of Remuneration Committee, Member of Complaints Committee and Member of Technical Committee
    19.00KN/A
    Mr. Tom Tang Hogg BSc,MBA, 49
    Chief Exec. Officer, Exec. Director, Member of Complaints Committee and Member of Technical Committee
    1.00MN/A
    Mr. Chig Fung Cheng BEc, CA, 48
    Chief Financial Officer and Exec. Director
    512.00KN/A
    Ms. Edith Shih BSE, MA, EdM, Solicitor, FCIS, FCS(PE), 63
    Company Sec., Non-Exec. Director and Member of Complaints Committee
    19.00KN/A
    Ms. Yuan Zhao ,
    Investment Mang.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.